That you still can't spot too good to be true for your faux oh but what about liberal outrages.. When I was a kid we were made to feel ashamed for being dumb. Guess you did not have enough of that.
Latest Vaccine News
- Thread starter gwb-trading
- Start date
That you still can't spot too good to be true for your faux oh but what about liberal outrages.. When I was a kid we were made to feel ashamed for being dumb. Guess you did not have enough of that.
Glad you came to grips with your childhood problems, personally never suffered from such.
Glad you came to grips with your childhood problems, personally never suffered from such.
Havering a father who did not put up with stupid is clearly not something you suffered from.
But we do now..
Oxford Covid Vaccine Protects Three Months After One Dose And May Reduce Transmission
The jab could have a "substantial effect" on reducing transmission of coronavirus, Oxford University analysis finds.
https://www.huffingtonpost.co.uk/en...sion_uk_60198aa7c5b622df90f739cc?guccounter=1
One jab of the Oxford University and AstraZeneca vaccine offers 76% protection against Covid-19 for up to three months, a study has shown.
The finding is a boost for Britain’s controversial decision to extend the gap between the first and second doses of the vaccine to 12 weeks.
Oxford University said the findings of the pre-print paper show the jab also had a “substantial effect” on reducing transmission of the disease.
Before these results, little was known about how effective the Covid-19 vaccines were at preventing transmission of the disease.
Britain has decided to give as many people as possible some protection by lengthening the amount of time between initial shots and booster shots of Covid-19 vaccines.
Oxford academics said: “Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76%, and modelled analysis indicated that protection did not wane during this initial three month period.”
The paper said that vaccine efficacy was 82.4% with 12 or more weeks to the second dose, compared to 54.9% for those where the booster was given under six weeks after the first dose.
The authors also reported a 67% reduction in transmission after the first dose of the vaccine based on swabs obtained from volunteers in the UK arms of the trial.
The report states that the vaccine “may have a substantial impact on transmission by reducing the number of infected individuals in the population”.
The results, gathered from trials in Britain, Brazil and South Africa, indicated that immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.
Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial, and study co-author, said: “These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA (Medicines and Healthcare products Regulatory Agency) and EMA (European Medicines Agency) to grant the vaccine emergency use authorisation.
“It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine.”
The jab could have a "substantial effect" on reducing transmission of coronavirus, Oxford University analysis finds.
https://www.huffingtonpost.co.uk/en...sion_uk_60198aa7c5b622df90f739cc?guccounter=1
One jab of the Oxford University and AstraZeneca vaccine offers 76% protection against Covid-19 for up to three months, a study has shown.
The finding is a boost for Britain’s controversial decision to extend the gap between the first and second doses of the vaccine to 12 weeks.
Oxford University said the findings of the pre-print paper show the jab also had a “substantial effect” on reducing transmission of the disease.
Before these results, little was known about how effective the Covid-19 vaccines were at preventing transmission of the disease.
Britain has decided to give as many people as possible some protection by lengthening the amount of time between initial shots and booster shots of Covid-19 vaccines.
Oxford academics said: “Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76%, and modelled analysis indicated that protection did not wane during this initial three month period.”
The paper said that vaccine efficacy was 82.4% with 12 or more weeks to the second dose, compared to 54.9% for those where the booster was given under six weeks after the first dose.
The authors also reported a 67% reduction in transmission after the first dose of the vaccine based on swabs obtained from volunteers in the UK arms of the trial.
The report states that the vaccine “may have a substantial impact on transmission by reducing the number of infected individuals in the population”.
The results, gathered from trials in Britain, Brazil and South Africa, indicated that immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.
Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial, and study co-author, said: “These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA (Medicines and Healthcare products Regulatory Agency) and EMA (European Medicines Agency) to grant the vaccine emergency use authorisation.
“It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine.”
The UK is also vaccinating their citizens at 5x the rate of the rest of the EU - there is much talk about how Brexit made this possible. If they can get their economy up and running quicker than the Euros they will have gained an important advantage which they can leverage to curtail some of the losses they suffered from Brexit.
That has nothing to do with Brexit. The UK approved already the vaccine beginning of december while the rest of Europe was following the normal procedure and waiting for the pjase 3 results. The rest op Europe approved only in 2021. So logically the UK has a higher number of people that got already vaccinated. Boris Johnson had political reasons to take the risk to start too early. He wanted to take away the attention of the huge Brexit problems.
In Northern Ireland shops are half empty.
UK online shops have big losses because of sales in EU. Before Brexit, clients could return goods if they were not satisfied. Because the UK is not part of the EU anymore, these returns become so costly that British online shops refuse to take back the goods and prefer to write off these returns as a loss. The cost of importing the goods back to the UK is too high and costs millions. So UK online shops lose clients and lose goods that are never paid for.
https://www.bbc.com/news/business-55757931
If a european buys a mobile phone for 100 euro online in the UK, he has 152 euro extra costs (declaration and administration cost, import taxes...). Result is no sales to EU anymore.
Export of fish to EU crashed and prices crashed too.
On a daily basis new problems arise and people notice that things became complex and expensive.
Brtish companies that want to do business in EU are opening now subsidiary companies in the EU, invest in warehouses and more stocks to avoid stock ruptures. All this costs extra money, just to be able to keep sales at the level from before Brexit.
Thank you. This was very insightful.
I have a question, do you know if the U.K. were still in the EU would Johnson have been able to approve early use of the vaccines?
I think that the whole vaccine story had no impact on the EU vision about the UK.
Each country in the EU can chose independently when and which vaccine to buy. The EU only tried to organize the volume of vaccines needed by the member states to avoid a war between the member states to get served first.
It should be noted that using a vaccine in the EU requires EU level approval. This is why EU countries had to wait to the end of December to start vaccinating; they were waiting for EU approval.
This, of course, was followed immediately by vaccine shortages when the manufacturers failed to deliver on their commitments to EU countries.